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PURPOSE. To investigate the slow and fast rod signals of the
scotopic 15-Hz flicker ERG in patients with molecularly con-
firmed Stargardt disease type I (STGD1). There is evidence that
these slow and the fast rod ERG signals can be attributed to the
rod bipolar–AII cell pathway and the rod–cone coupling path-
way, respectively.
METHODS. Twenty-seven patients with STGD1 with mutations
in both alleles of the ABCA4 gene were included. Scotopic ERG
response amplitudes and phases to flicker intensities ranging
from 3.37 to 0.57 log scotopic troland  sec (log scot
td  sec) were measured at a flicker frequency of 15 Hz. In
addition, scotopic standard ERGs were obtained. Twenty-two
normal subjects served as controls.
RESULTS. The amplitudes of both the slow and fast rod ERG
signals were significantly reduced in the STGD1 group. The
phases of the slow rod signals lagged significantly, whereas
those of the fast rod signals did not. The standard scotopic ERG
did not reveal significant alterations.
CONCLUSIONS. The results provide evidence that a defective
ABCA4 transporter can functionally affect both the rod bipo-
lar–AII cell pathway and the rod–cone coupling pathway. In
STGD1, the scotopic 15-Hz flicker ERG may reveal subtle ab-
normalities at different sites within the rod system that remain
undetected by standard ERG techniques. (Invest Ophthalmol
Vis Sci. 2002;43:1248–1256)
The protein ABCA4 (formerly ABCR) is a rod and conecell-specific member of the ATP-binding cassette family of
transporters. It was independently identified as an abundant
250-kDa photoreceptor outer segment membrane protein1–4
and as the protein product of a retina-specific gene, ABCA4,
that is mutated in chromosome 1–linked autosomal recessive
Stargardt macular dystrophy-fundus flavimaculatus (STGD1;
Online Mendelian Inheritance in Man [OMIM]: 248200; pro-
vided by the National Center for Biotechnology, Bethesda, MD,
and available at http://www3.ncbi.nlm.nih.gov/omim/).5 Mu-
tations in ABCA4 responsible for STGD1 are found throughout
the protein-coding region.5–10 The clinical disease was first
described by the German ophthalmologist Karl Stargardt as a
unique macular dystrophy characterized by visual loss in the
first two decades of life in combination with an atrophic lesion
of the macula.11 Franceschetti later used the term fundus
flavimaculatus to denote a retinal dystrophy characterized by
yellow flecks found in the distal retina at the posterior pole of
the eye.12 Intrafamilial coexistence of the two different fundu-
scopic patterns has been observed frequently,13 and linkage
analysis has recently revealed that Stargardt macular dystro-
phy and fundus flavimaculatus genetically represent a single
disorder.14
Clinically, STGD1 compromises mainly macular func-
tion,15 and recently it has been shown that ABCA4 is ex-
pressed both in foveal and peripheral cones.16 In accor-
dance with ABCA4 expression in cones, we showed recently
that patients with STGD1 can exhibit substantial amplitude
and phase alterations of long (L)- and middle (M)-wavelength
cone driven photopic ERGs with a large interindividual
variability.17 However, in previous studies ABCA4 appeared
to be a protein exclusively confined to rod outer segments,5
and studies in ABCA4 knockout mice point to an important
role of the rod system in the pathophysiology of the dis-
ease.18 To better understand the ABCA4-mediated mecha-
nism in human disease, the investigation of rod function in
patients carrying ABCA4 mutations is advisable. ERG surveys
on rod function involving standard techniques have been
equivocal.13,19 –26 Moreover, in none of these studies have
the patients been genotyped.
Our preliminary observations have suggested that subtle
deterioration within the rod system that is not visible with
the standard rod ERG may be detected by means of the
scotopic 15-Hz flicker ERG in patients with molecularly
confirmed STGD1.27 Moreover, there is plenty of evidence
that the slow and fast rod signals derived from the scotopic
15-Hz flicker ERG reflect electrophysiological activity driven
by two different rod circuitries: the rod bipolar–AII cell
pathway and the rod– cone coupling pathway, respective-
ly.28 –30 Histologic studies of the human retina in STGD1
have reported Mu¨ller cell hypertrophy and lipofuscin gran-
ules in the inner segments.31 These changes may well alter
postreceptoral rod function. Therefore, the purpose of the
present study was to extend ERG testing in STGD1 toward a
protocol capable of testing function of different postrecep-
toral rod circuitries.
Although it is undisputed that typical STGD1 is an autoso-
mal recessive disorder in most affected families, standard tech-
niques identify mutations in only approximately 60% of ABCA4
alleles.6,7,10 Thus, it is mandatory for a study attempting to
correlate retinal function with the STGD1 genotype to be
confined to those patients in whom both mutant alleles have
been identified. We therefore exclusively included in our study
patients with STGD1 who had mutations in both alleles of the
ABCA4 gene.10
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METHODS
Patients with STGD1 and Normal Subjects
Twenty-seven patients were included in the study. A detailed history
(including family history) was obtained and a comprehensive ophthal-
mic examination (including visual acuity, which was measured on a
quasilogarithmic ordinal scale; for use in regression models it was
ranked 1–10 and treated as quasicontinuous) was performed. Fundus
appearances were assessed by slit lamp biomicroscopy and color
fundus photographs. In the literature, there is no uniform classification
of the fundus changes in STGD1. As previously reported,17 we staged
the central fundus changes from mild (normal to diffuse foveal reflex,
subtle pigment mottling of the macular retinal pigment epithelium
[RPE], tapetal sheen or beaten-bronze reflex), to moderate (pro-
nounced hyper- and hypopigmentation of the macular RPE, bull’s-eye
atrophy), to severe (widespread confluent areas of RPE and/or choroi-
dal atrophy). In addition, the existence and distribution of the typical
white-yellow flecks at the level of the RPE were staged: () no flecks;
() flecks confined to the posterior pole (i.e., within the vascular
arcades); and () peripheral flecks extending beyond the vascular
arcades. The fundus alterations were very similar in the two eyes in
each patient. For statistical analysis, we evaluated the fundus features
(distribution of flecks) of only one eye (which was randomly chosen).
Twenty-two normal subjects served as the control. Detailed ERG
data on this group of normal subjects have been published pre-
viously.27 Both the 15-Hz scotopic flicker ERG and the scotopic stan-
dard ERG were recorded from the same set of normal subjects.
Informed consent was obtained from all subjects after explanation
of the purpose and possible consequences of the study. This study was
conducted in accordance with the tenets of the Declaration of Helsinki
and with the approval of our institutional ethics committee on human
experimentation.
Mutation Analysis in the ABCA4 Gene
The 27 patients were selected from a large study group, based on their
harboring disease-associated mutations on both ABCA4 alleles.10 De-
tails on the mutation analysis are fully described elsewhere.10
ERG Stimulation, Recording, and Procedure
The apparatus, the stimulation, and the procedure of the ERG mea-
surements have been reported.27 Briefly, we used a Ganzfeld stimulator
(LKC Technologies, Inc., Gaithersburg, MD) and data acquisition sys-
tem (Universal Testing and Analysis System-Electrophysiology 2000
[UTAS-E 2000]; LKC Technologies, Inc.). Stimulus and recording con-
ditions were in accordance with the International Society for Clinical
Electrophysiology of Vision (ISCEV) standard.32 The subjects, posi-
tioned with the aid of a headrest, viewed into the center of a Ganzfeld
bowl. The bowl was homogeneously illuminated by white flashes
repeated at a frequency of 15 Hz produced by a xenon discharge lamp
(flash duration 10 s; correlated color temperature 6000 K; see
Table 1 [2.4.4] in Ref. 33). The flicker yielded by this device was full
field. To avoid stray light, we masked all sites of light leakage by black
tape. In addition, the subjects were surrounded by a black curtain so
that accidental light or stray light (e.g., arising from the computer
monitor) had no influence on the Ganzfeld illumination and the ERG
recording. Each flash was triggered by the testing system’s computer
(UTAS-E 2000; LKC Technologies, Inc.), which was also used to store
and analyze the ERG recordings. Maximal intensity was 1.43 log
scotopic troland  sec (log scot td  sec). To attenuate the flash, neutral
density (ND) filters (Wratten; Eastman Kodak, Rochester, NY)
mounted in a filter wheel were inserted. The maximum attenuation
was 4.8 log units ND and the step size was 0.2 log units ND. Thus, the
minimum stimulus intensity was at approximately 3.37 log scot
td  sec. We continued the measurements up to a retinal illuminance of
0.57 log scot td  sec, which is well below the cone threshold in the
Ganzfeld ERG (approximately 0.75 log scot td  sec34).
Each subject was dark adapted for 30 minutes. In the normal
subjects, one eye was dilated with a mydriatic agent (0.5% tropic-
amide), and in the patients, tropicamide (0.5%) and phenylephrine
(5%) were used. Pupil diameters were determined before ERG record-
ings. There was no difference in pupil diameter between the two
subject groups. Dawson, Trick, Litzkow (DTL) fiber electrodes were
positioned on the conjunctiva directly beneath the cornea and at-
tached at the nasal and lateral canthus. Reference electrodes (Ag-AgCl)
were placed over both temporal bones, and a ground electrode was
placed on the forehead. The ERG responses to the periodic flashes
were recorded and stored by means of the testing system’s computer.
To avoid the effects of the rapid changes of gain control mechanisms
in the rod system that accompany the onset of flickering lights, we
discarded the responses to the flashes presented during the first 5
seconds. The signals were bandpass filtered (1–70 Hz) and averaged 50
to 100 times online. The noise level was determined by recording an
ERG signal with the xenon discharge lamp covered by black cardboard
(similar to a published procedure35). In addition, we performed a
scotopic ERG according to the ISCEV standard,32 by using the same
setup. For the rod response (b-wave), the patients and normal subjects
were dark adapted for at least 30 minutes before recording began. The
stimulus was a dim white flash of 0.97 log scot td  sec (2.4 log units
below the standard white flash). For the maximal combined response
(a-wave and b-wave), we then used a standard white flash of 1.43 log
scot td  sec.
Data Analysis
To determine the periodicity of the ERG responses, we computed a
fast Fourier transform (FFT) on the sampled data.36,37 As a result, we
found that all responses were dominated by the fundamental compo-
nent.27 Therefore, we identified the ERG response amplitude and
phase as the amplitude and phase of this fundamental component. In
a previous study in normal subjects, we found that the flicker null (and
the large phase shift of approximately 180°) occurs between intensities
of 1.77 and 1.37 log scot td  sec.27 Therefore, the ERG signals at
flicker intensities between 3.37 and 1.97 log scot td  sec (eight
intensity levels) were considered to be dominated by the slow rod ERG
signals and ERG signals between 1.17 and 0.57 log scot td  sec
(four intensity levels) by the fast rod ERG signals.
Statistical Analysis
Data were analyzed by computer (JMP software, ver. 4.0.2; SAS Insti-
tute, Inc., Cary, NC). Results with P  0.05 were considered statisti-
cally significant. For descriptive statistics (such as the median and the
percentiles for the standard ERG measures), we considered both the
right and left eyes of each patient. To estimate how many patients with
STGD1 exhibited abnormal ERG signals of the two rod ERG pathways,
we summed up the ERG amplitudes obtained at flicker intensities
between 3.37 and 1.97 log scot td  sec (for the slow rod ERG
pathway) and those obtained at flicker intensities between 1.17 and
0.57 log scot td  sec (for the fast rod ERG pathway) and compared
this measure with the normal 5th percentile.
For hypothesis testing, the amplitudes and implicit times of the
slow and fast rod ERG signals of the patients with STGD1 were
compared with those of normal subjects by a multivariate repeated-
measures analysis of variance (MANOVA) with an “eye” factor, because
the data from patients in the STGD1 group were from two eyes that are
not independent.38 Thus, we tested the difference between the mul-
tivariate means of the normal subjects’ and the patients’ eyes with
degrees of freedom equal to the number of persons and countered the
larger variation in the patients’ ERG responses amplitude and phases by
effectively averaging over the two eyes of each patient. In a recent
study on patients with X-linked congenital stationary night blindness
carrying mutations in the NYX gene, the same statistical approach was
used.39
To evaluate interocular differences in the patients’ group we cal-
culated the median of the differences between the two eyes of each
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patient at every flicker intensity level for both the logarithm of the ERG
amplitude and the ERG response phase. To correlate the intraindi-
vidual interocular differences with the visual acuity, we calculated the
difference of the amplitudes and phases of the better eye (in visual
acuity) minus those of the worse eye. For every intensity level, we then
calculated the mean  SE of all the patients’ data and tested the
hypothesis that this difference is zero.
For the standard ERG parameters, a similar analysis of variance
(ANOVA) with the patient as a random factor was used. We further-
more performed a multivariate repeated-measures analysis of covari-
ance (MANCOVA) to assess the effect of explanatory variables such as
age, age-adjusted disease duration, visual acuity, and distribution of
flecks on both the scotopic 15-Hz flicker ERG and the standard rod
ERG. How standard ERG and slow and fast rod ERG measures coincide
was described by canonical correlation (i.e., the maximal correlation
between linear combinations).
RESULTS
Group Characteristics
The ages of the patients with STGD1 (range, 13–55 years;
median, 32) did not differ significantly (P  0.95, unpaired
t-test) from those of the 22 normal subjects (range, 19–58
years; median, 29.5). Subject groups did not differ in their
proportion of male-to-female subjects (P  0.39, two-tailed
Fisher exact test). Clinical data on the patients with STGD1 are
shown in Table 1.
Mutation Analysis in the ABCA4 Gene
In the 27 patients with STGD1 included in the study, disease-
causing mutations were identified in all 54 ABCA4 alleles10
(Table 1). Eleven patients were found to carry missense muta-
tions in both alleles, whereas 11 patients had a missense mu-
tation in one and a second mutation in the other allele, which
is expected to result in a truncated protein (i.e., two nonsense,
two frameshift, seven splice mutations). Five patients (num-
bers 15, 18, 19, 26, 27) were shown to have a 2588G3C splice
mutation in one allele in combination with a nonsense
(Q1412X or Q1750X) or a splice (IVS352T3A) mutation in
the other allele (Table 1).
Amplitudes of the Slow and Fast Rod ERG Signals
Figure 1 displays the original ERG signals to visual stimulation
of the 15-Hz flicker at scotopic conditions in a normal subject
(left) and a patient with STGD1 (patient 15; right). In the
normal subject, the ERG signal increased slightly with increas-
ing flicker intensity from 3.37 to 2.97 log scot td  sec and
then decreased thereafter. There was a gradual increase (ad-
vance) in the response phase with increasing flicker intensity.
At flicker intensities between 2.17 and 1.77 log scot
td  sec, there was a minimum in ERG response. To higher
flicker intensities (from 1.37 to 0.97 log scot td  sec), the
ERG signal rapidly increased again in amplitude and was con-
siderably phase advanced. In patient 15, the features described
for the normal subject were similar; however, the patient
displayed reduced ERG signals for both the lower and the
higher flicker intensity ranges, even though the patient’s am-
plitudes were considerably above the median of those of the
patients with STGD1 as a group.
The ERG signals were Fourier analyzed, and the amplitude
and phase of the fundamental component were determined. In
Table 1, we provide a surrogate of the signal reduction within
TABLE 1. Characteristics of the 27 patients with STGD1
Patient Sex Age Onset
VA
(OD)
VA
(OS) CFC DF Mut(1) Mut(2)
Slow Rod
ERG
Fast Rod
ERG
1 M 32 9 1/50 20/400 Severe  Q1412X R2077W 19.2 12.1
2 M 49 17 20/200 20/200 Severe  768G3T G1961E 56.1 23.8
3 M 46 30 20/40 20/200 Mild  E471K G1961E 31.7 29.0
4* M 27 19 20/32 20/100 Moderate  2588G3C E1885K 35.0 45.1
5* M 31 18 20/400 20/400 Severe  2588G3C E1885K 36.1 39.1
6* F 29 12 20/200 20/200 Moderate  2588G3C E1885K 23.4 8.1
7 F 23 18 20/400 20/400 Mild  E1399K G1977S 103.5 39.3
8 M 28 17 20/200 20/200 Mild  R1898H G1975R 44.4 19.5
9 M 39 29 20/100 20/200 Moderate  G607R G1961E 45.8 20.7
10 F 23 17 20/200 20/200 Mild  P68L S1689P 80.2 25.9
11 F 33 30 20/50 20/50 Mild  E1399K G1961E 49.8 62.0
12 M 50 42 20/400 20/64 Severe  2588G3C L541P/A1038V 53.8 30.2
13 M 36 25 20/40 20/32 Moderate  296insA A1038V 88.2 40.0
14 F 55 16 HM HM Severe  Q635K IVS405G3A 11.7 11.2
15 F 27 25 20/100 20/50 Moderate  2588G3C Q1412X 65.8 71.5
16 F 45 14 1/50 1/35 Severe  L541P/A1038V S1063P 16.4 16.6
17 M 40 23 20/100 20/200 Moderate  296insA G1961E 46.1 58.3
18** M 35 15 20/400 20/400 Moderate  2588G3C Q1750X 14.1 12.9
19** M 43 14 HM HM Severe  2588G3C Q1750X 17.4 8.6
20 F 32 8 20/200 20/200 Severe  G1961E G1961E 66.2 79.0
21 F 23 12 20/400 20/400 Mild  R212C T9591 24.6 25.3
22 F 29 9 20/200 20/200 Moderate  L541P/A1038V G1961E 72.3 31.8
23 M 20 9 20/400 20/400 Moderate  L541P/A1038V IVS405G3A 64.7 42.2
24 F 39 23 20/400 20/50 Moderate  W663X G1961E 92.6 68.8
25 F 41 36 20/200 20/64 Severe  F1440V G1748R 97.2 52.7
26*** M 13 10 20/100 20/200 Moderate  R572Q/2588G3C IVS352T3A 59.2 33.5
27*** M 16 15 20/200 20/200 Moderate  R572Q/2588G3C IVS352T3A 31.1 22.9
Age at examination (y), gender, age of onset (y), visual acuity (VA), central fundus changes (CFC), and existence and distribution of the typical
white-yellow flecks (DF) are shown. In addition, the molecular genetic findings in the ABCA4 gene are specified (Mut 1 and 2). The last two
columns provide the percentage of ERG amplitude for the slow and fast rod ERG signals (average of the right and left eye) compared with the mean
of the normal subjects for the individual patients (for calculation procedure see Ref. 27).
* Siblings. HM, visual acuity decreased to hand motions.
1250 Scholl et al. IOVS, April 2002, Vol. 43, No. 4
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933593/ on 07/05/2017
the two rod ERG pathways for each patient separately (for
calculation procedure, see Ref. 27). The data in the table allow
a qualitative estimation of the severity of rod dysfunction in
view of the mutation pairings and the other clinical parame-
ters, such as age of onset. For instance, patient 20, who was
homozygous for the G1961E mutation, exhibited the earliest
onset (8 years of age) but relatively mild reductions of both the
slow and fast rod ERG signals. This is also true of patients 22
and 23 (onset at 9 years). Patient 1, however, who also showed
an early onset (9 years), carrying the mutations Q1412X and
R2077W, exhibited severely reduced amplitudes of the slow
and fast rod ERG signals. Patient 13, carrying the mutations
296insA and G1961E, exhibited the latest onset (42 years). The
amplitude reductions for both the slow and fast rod ERG
signals, however, were near the median of the patient study
group.
In Figure 2, the noise level and the median, the 5th and 95th
percentiles of both the normal subjects and the patients with
STGD1 are displayed. As a group, the patients exhibited con-
siderably reduced amplitudes for both the slow and the fast rod
ERG signals. However, there was an overlap between the data
sets of patients and normal subjects. Considering the summed
ERG amplitudes for the slow and fast rod signals for each eye
of each patient, 19 and 37 of 54 eyes, respectively, were below
the normal 5th percentile.
To explore whether the two subject groups showed statis-
tically significant differences, the amplitudes of the slow (eight
intensity levels) and the fast (four intensity levels) rod ERG
signals were statistically analyzed using a repeated-measures
MANOVA with the factors “disease” and “eye nested under
subject and disease.” Because residuals of amplitudes for both
rod ERG pathways do not have a normal distribution, we
converted amplitudes into their logarithms, which had normal
distributed residuals. For the two rod ERG pathways, the
FIGURE 1. Original tracings of the
rod ERG responses to 15-Hz flicker
stimulation obtained from a normal
subject (left) and a patient with
STGD1 (patient 15, right). Shown is
250 ms of the ERG signal. The origin
of the x-axis indicates stimulus onset.
On the y-axis, the flicker intensity at
which the ERG response was ob-
tained is shown. Step size is 0.4 log
units ND attenuation of the maximal
intensity, beginning with the lowest
intensity of 3.37 log scot td  sec
(top). One division indicates 5 V. In
the normal subject, two features
were observed: The amplitude in-
creased somewhat with increasing
flicker intensity and then decreased
to a minimum at 1.77 log scot
td  sec with a rapid increase of the
ERG response amplitude thereafter.
With increasing flicker intensity,
there was a shift of the timing of the
ERG signal toward larger phases (cor-
responding to shorter implicit times,
arrow). The features in the patients
with STGD1 were similar, but there
was a considerable amplitude loss for
both the lower and higher flicker
intensities.
FIGURE 2. Rod ERG amplitudes to 15-Hz flicker stimulation with in-
creasing flicker intensity in the normal subjects and the patients with
STGD1. In the patients with STGD1, considerable amplitude decreases
were observed in both the slow and the fast rod ERG signals. The
probabilities indicate the results obtained by MANOVA of the ampli-
tude data.
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MANOVA revealed significantly lower amplitudes in the pa-
tients with STGD1 for both the slow (F test, exact F  16; P 
0.0002) and the fast (F  31; P  0.0001) rod ERG signals. The
intraindividual interocular differences were considerably low
(median for the slow rod ERG signals between 0.09 and 0.13
V; for the fast rod ERG signals between 0.07 and 0.15 V)
indicating that the amplitude data were very similar in the two
eyes in individual patients. Probabilities for testing the hypoth-
esis that eyes with better visual acuity exhibited larger ampli-
tudes ranged between 0.20 and 0.80 for the slow rod ERG
signals and between 0.30 and 0.80 for the fast rod ERG signals,
indicating that there was no significant correlation of intra-
individual differences.
To test for the relationship between the clinical parameters
(age, age-adjusted disease duration, visual acuity, distribution
of flecks; see Table 1) and the amplitudes of the slow rod
ERG pathway, a repeated-measures MANCOVA was used. The
MANCOVA revealed that all these clinical parameters together
influenced the amplitude data significantly (F  4.8; P 
0.0007). However, just one single regressor had a probability
just less than 0.05—namely, visual acuity (F  4.7; P  0.04).
For the fast rod ERG pathway, a similar MANCOVA revealed
that the combination of age, age-adjusted disease duration,
visual acuity, and the distribution of flecks influenced the
amplitude data significantly (F  4.6; P  0.0009). However,
no single regressor influenced these ERG amplitudes signifi-
cantly.
Phases of the Slow and Fast Rod ERG Signals
Consistent with destructive interference between the slow and
fast rod ERG signals being the cause of the amplitude minimum
shown in Figures 1 and 2, the phase of the ERG responses
abruptly increased by approximately 180° (corresponding to a
half cycle) as the amplitude minimum was crossed (Fig. 3). For
the phases of the slow rod ERG signal, a considerable decrease
(corresponding to a slowing of the signal, provided that a time
delay difference is the cause of the phase difference) was
observed in the patients with STGD1. This was true of each of
the eight phases obtained at the lower flicker intensities (Fig.
3). Of the phases obtained at the highest flicker intensities
corresponding to the fast rod ERG signals, only the ERG re-
sponse phase obtained at 1.17 log scot td  sec showed a
noticeable reduction, whereas the phases obtained at flicker
intensities between 0.97 and 0.57 log scot td  sec were
rather similar to those of the normal subjects (Fig. 3).
As performed for the amplitude data, the phases of the slow
and the fast rod ERG signals were statistically analyzed using a
repeated-measures MANOVA with factors “disease” and “eye
nested under subject and disease.” The MANOVA revealed that
the phases of the slow rod ERG signals lagged significantly in
the patients with STGD1 (F  16.7; P  0.0003) but not those
of the fast rod ERG signals (F 3.6; P 0.07). The ERG phases
of neither the slow pathway (F  1.3; P  0.30) nor the fast
pathway (F  1.2; P  0.36) were significantly influenced by
the clinical parameters: age, age-adjusted disease duration, vi-
sual acuity, and the distribution of flecks. Similarly to the
amplitude data, the intraindividual interocular differences
were considerably low (median for the slow rod ERG signals
between 6° and 13°; for the fast rod ERG signals between 4°
and 9°). Probabilities for testing the hypothesis that eyes with
better visual acuity exhibited larger ERG response phases (cor-
responding to shorter implicit times) ranged between 0.04 and
0.64 for the slow rod ERG signals and between 0.09 and 0.66
for the fast rod ERG signals, but a subsequent Bonferroni-Holm
adjustment to correct for multiple comparisons (multiple  
0.05) revealed that none of these measures was significant.
Standard Scotopic ERG
A summary of all standard ERG measures of individual patients
with STGD1 is given in Table 2. The amplitudes of the scotopic
rod b-wave, the scotopic a-wave, and the b-wave of the maxi-
mal response were below the normal 5th percentile in 22, 14,
and 15, of 54 eyes, respectively (Table 2). The implicit times of
the scotopic rod b-wave, and the a- and the b-wave of the
maximal response were above the 95th percentile in the
normal subjects in 15, 12, and 22 of 54 eyes, respectively
(Table 2).
The amplitudes and implicit times of the standard scotopic
ERG were statistically analyzed with an ANOVA. For the
scotopic rod b-wave amplitude to a dim white flash, the
ANOVA revealed a lower mean in the STGD1 group (t  2.5;
P  0.02), but there was no difference in implicit time (t 
0.71; P 0.48). The scotopic a-wave was lower in amplitude
(t 2.3; P 0.03) and prolonged in implicit time (t 2.6; P
0.01). For the scotopic b-wave to the maximal flash, there was
no difference in amplitude (t  2.0; P  0.06), but the implicit
time was prolonged in the patients with STGD1 (t2.5; P
0.02). The b- to a-wave ratio did not show a difference (t 
0.58; P  0.56). A subsequent Bonferroni-Holm adjustment
to correct for multiple comparisons (multiple   0.05), how-
ever, revealed that none of these measures exhibited signifi-
cant differences between subject groups.
We also examined the canonical correlation of the ampli-
tudes and phases of both the slow and fast rod ERG signals with
the respective measures derived from the standard ERG (Table
3). Generally, the amplitude data were highly correlated,
whereas there were only weak or moderate correlations be-
tween ERG phases and ERG implicit times. Subsequent Bon-
ferroni-Holm adjustments (multiple   0.05) revealed that all
correlations between the amplitude data were significant,
whereas only the phases of the slow rod ERG signals and the
a-wave implicit time were significantly correlated, and all other
correlations between phase data and implicit times were not.
DISCUSSION
In a group of 27 patients with STGD1 who had mutations in
both alleles for the ABCA4 gene we found significantly de-
creased amplitudes for both the slow and fast rod signals
FIGURE 3. Rod ERG phases to 15-Hz flicker stimulation with increas-
ing flicker intensity in the normal subjects and the patients with
STGD1. In slow rod ERG signals, the patients with STGD1 showed
considerably reduced phases, whereas the phases were rather similar
between the two subject groups in fast rod ERG signals. The probabil-
ities indicate the results obtained by the MANOVA of the phase data.
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derived from the scotopic 15-Hz flicker ERG. The ERG re-
sponse phase of the slow rod signals lagged significantly. The
amplitude data exhibited significant correlation between the
scotopic 15-Hz flicker ERG and the standard rod ERG, whereas
this was not generally the case for the ERG timing. The abnor-
malities of the standard rod ERG measures themselves did not
reach statistical significance, although 41% of the eyes tested
exhibited subnormal rod b-wave amplitudes.
In previous studies involving the scotopic standard ERG,
investigators have reported equivocal results. Moreover, in
these studies patients were not genotyped. In one study, highly
significant amplitude losses were reported in STGD1,23
whereas in another study all patients showed completely nor-
mal scotopic ERGs.21 In other studies, only a minority of
patients with STGD1 exhibited reduced scotopic rod
b-waves,13,20,22,24–26,40 which is in accordance with our find-
ings. It is known that STGD1 exhibits a large interindividual
variability in clinical severity (e.g., Refs. 19,41), which is also
true for our group of patients with STGD1. This may explain
why our patients with STGD1 as a group did not show a
statistically significant reduction in ERG amplitude or an in-
crease in implicit time. In the majority of previous studies,
however, the timing of the scotopic rod b-wave has not been
investigated. In a few studies, either mildly or rarely abnormal
implicit times were reported,24 which is in accordance with
our results, whereas in another complete normality was
reported.21 We conclude that standard ERG techniques may
fail to detect subtle deterioration within the rod system in
STGD1.
Anatomic and physiological studies of the mammalian retina
have revealed the existence of separate rod pathways. Rods are
thought to synapse with a single type of bipolar cell, the rod
ON bipolar cell.42–44 This cell, in turn, contacts the AII ama-
crine cell at a sign-preserving glutamate synapse.45–49 Signals
from the AII cell then infiltrate the main cone circuitry by
exciting ON cone bipolar cells and inhibiting OFF cone bipolar
cells.46,49–51 Thereafter, ON bipolar cells excite ON ganglion
cells, and OFF bipolar cells excite OFF ganglion cells. A second
pathway (the rod–cone coupling pathway) infiltrates the
ON and OFF cone bipolar circuitry at the earliest possible
stage, through gap junction contacts between rod and cone
photoreceptors, facilitating electrical transmission.47,52–54
Through these gap junctions, signal flow involves ON and
OFF cone bipolar cells and thereafter ON and OFF ganglion
cells.47,53,55,56 There is plenty of evidence from electrophysi-
ological and psychophysical studies by Stockman et al.28,29 and
TABLE 2. Scotopic Standard ERG of the Patients with STGD1
Patient
Rod Response b-Wave a-Wave
Maximum Response:
b-Wave
b- to a-
Wave RatioAmplitude
Implicit
time Amplitude
Implicit
time Amplitude
Implicit
time
OD OS OD OS OD OS OD OS OD OS OD OS OD OS
1 95.1 117.7 96.5 97.5 73.2 84.8 19.0 19.5 185.4 261.6 56.5 58.5 2.53 3.09
2 175.6 181.7 104.5 105.5 205.5 186.6 21.5 21.0 371.3 351.8 51.0 51.0 1.81 1.89
3 232.3 238.4 96.5 95.5 282.9 253.7 21.0 21.0 442.1 397.6 45.5 46.0 1.56 1.57
4 195.1 176.2 104.0 105.5 156.7 135.4 22.0 22.5 369.5 317.7 47.5 47.5 2.36 2.35
5 170.1 226.2 110.5 111.0 174.4 189.0 22.0 22.5 462.2 536.0 49.0 49.0 2.65 2.84
6 185.4 151.2 106.5 103.5 143.3 172.6 21.5 21.5 419.5 398.2 47.0 46.5 2.93 2.31
7 364.6 536.6 92.5 103.0 205.5 241.5 21.5 17.0 482.3 611.6 48.0 49.5 2.35 2.53
8 197.0 103.7 111.5 112.5 189.6 120.7 23.0 23.5 298.2 204.3 50.5 48.0 1.57 1.69
9 181.1 207.3 70.5 78.5 254.3 262.2 21.5 20.5 558.5 559.8 43.0 46.5 2.20 2.13
10 242.7 182.3 74.5 77.0 216.5 218.3 16.5 15.5 372.0 403.1 46.0 46.5 1.72 1.85
11 254.3 234.2 105.5 105.0 207.9 192.7 20.5 20.5 498.2 464.0 41.0 40.0 2.40 2.41
12 163.4 134.8 68.5 74.5 174.4 173.2 19.5 20.5 273.2 320.1 33.0 34.0 1.57 1.85
13 207.3 156.1 107.0 109.0 237.8 168.3 21.5 21.0 429.9 287.8 45.0 44.5 1.81 1.71
14 28.1 14.6 109.0 90.5 37.2 62.8 24.0 25.5 82.3 92.1 56.0 58.5 2.21 1.47
15 272.0 242.7 90.5 90.5 214.0 164.0 16.0 21.0 406.1 333.5 36.5 36.0 1.90 2.03
16 13.4 23.8 115.5 115.0 26.2 35.4 23.5 25.5 37.2 68.3 55.5 56.5 1.42 1.93
17 214.0 265.2 87.0 89.5 262.8 288.4 21.5 21.5 373.2 467.7 35.0 35.0 1.42 1.62
18 76.2 59.2 93.5 93.0 144.5 187.8 23.0 24.0 203.7 164.0 43.0 44.5 1.41 0.87
19 87.2 62.8 110.5 108.5 97.6 75.6 22.5 23.5 178.7 120.1 45.0 44.5 1.83 1.59
20 295.7 323.2 79.5 79.5 206.1 215.2 21.0 21.5 442.7 501.8 47.0 47.0 2.15 2.33
21 322.6 266.5 95.5 96.0 264.0 198.2 19.0 17.0 464.6 396.3 45.0 44.0 1.76 2.00
22 328.7 262.2 71.5 97.0 341.5 194.5 15.5 15.5 594.5 338.4 43.0 43.0 1.74 1.74
23 239.0 270.1 88.0 89.5 169.5 198.8 21.0 21.0 297.6 351.8 34.5 35.0 1.76 1.77
24 389.6 383.5 77.5 78.5 307.3 309.2 20.0 20.0 680.5 662.2 47.0 46.5 2.21 2.14
25 181.7 265.2 72.0 86.5 192.7 223.2 15.5 15.5 331.1 407.9 47.5 49.0 1.72 1.83
26 415.9 261.6 96.0 98.5 337.2 205.5 21.5 22.0 743.9 468.9 54.0 50.5 2.21 2.28
27 269.3 259.2 96.5 95.5 186.6 251.2 22.0 21.5 436.0 407.9 47.5 48.0 2.34 1.62
Median 212.5 96.0 200.3 21.3 387.5 46.8 1.85
5th perc 35.2 74.9 58.7 15.5 105.9 34.8 1.53
95th perc 372.2 111.6 274.3 24.0 592.2 56.9 2.71
Normal Median 268.3 91.0 222.6 20.5 438.4 43.3 1.89
Normal 5th perc 184.2 84.5 168.3 15.0 317.7 33.0 1.55
Normal 95th perc 435.4 105.0 282.9 22.0 537.2 47.0 2.39
Results of the ERG recordings according to the ISCEV standard of the individual patients. Scotopic rod b-wave amplitude (in microvolts) and implicit
time (in milliseconds), a-wave amplitude of the maximal response (in microvolts), and implicit time (in milliseconds), b-wave amplitude (in microvolts),
and implicit time (in milliseconds) of the maximum response, and the b- to a-wave ratio are shown for the right and left eyes. For the scotopic standard
ERG, the lower lines provide the median and the 5th and 95th percentiles of the patients (two-eye medians) and of the normal subjects.
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Sharpe and Stockman30 that the slow and fast rod ERG signals
revealed in the human scotopic 15-Hz flicker ERG reflect elec-
trophysiological activity driven by the rod bipolar–AII cell
pathway and the rod–cone coupling pathway, respec-
tively.28–30 In preliminary observations in two patients with
congenital stationary night blindness of the complete Schubert-
Bornschein type, Sharpe and Stockman30 could not find detect-
able fast rod ERG signals, which is inconsistent with their
model of a rod–cone coupling pathway. In a very recent study
in patients with CSNB1 who carried mutations in the NXY
gene, however, we could detect substantial fast rod ERG
signals,39 which provides further support for the model sug-
gested by Stockman et al.,28,29 Sharpe and Stockman,30 and
Sharpe et al.57,58
It cannot be ruled out, however, that a direct rod-to-cone
OFF bipolar cell pathway that has been recently described in
the wild-type mouse59 may be involved in generating the
scotopic 15-Hz flicker ERG. To date, however, it is unclear
whether this third rod pathway is common to all mammalian
retinas.60 It has been hypothesized29 that the scotopic 15-Hz
flicker ERG reflects electrical activity, mainly of rod and cone
bipolar cells, although many retinal elements (such as the
receptors, the rod–cone gap junctions, or the AII cells) could
be involved.
We provide evidence that in STGD1 both rod pathways can
be functionally affected. The scotopic 15-Hz flicker ERG may
reveal subtle abnormalities at different sites within the rod
system that remain undetected by standard ERG techniques.
Nevertheless, why the scotopic 15-Hz flicker ERG revealed
abnormalities for both the slow and fast rod ERG signals in the
patients as a group, whereas the standard ERG did not show
significant effects, remains speculative. The comparison, how-
ever, is complicated, because the single-flash ERG and the
scotopic 15-Hz flicker ERG are measured under very different
conditions: The single-flash ERG is measured with flashes that
are separated in time with the express purpose of avoiding the
effects of light adaptation, whereas the scotopic 15-Hz flicker
ERG is measured with prolonged trains of flashes. As a result,
light adaptation plays a much greater role in the production of
the scotopic 15-Hz flicker ERG than of the single-flash ERG
response.28 Moreover, the slow rod signals are obtained by
applying stimuli that are considerably less intense than the dim
white flash used to obtain the standard rod response.32 (The
standard rod b-wave is measured with flash intensities at which
we obtained the fast rod signals—i.e., 0.97 log scot td  sec;
cf. Figs. 1, 2, 3.) Therefore, it may be that alteration within the
slow rod ERG pathway generally cannot be detected by the
standard rod ERG. These considerations are specifically impor-
tant when comparing the measures of the two different ERG
techniques and may explain why there is only mild correlation
for the timing (Table 3).
Correlation of electrophysiological measures with clinical
parameters such as the fundus appearance was observed by
some investigators,13,19,25 whereas others denied such a cor-
relation.21 In accordance with the former, the amplitude loss
for both the slow and fast rod signals were highly correlated
with the combination of the clinical parameters: age, age-
adjusted disease duration, visual acuity, and the distribution of
flecks. However, apart from the significant correlation of visual
acuity and amplitude of the slow rod signals, no parameter
alone exhibited a significant correlation. We suggest that the
parameters such as visual acuity, disease duration, and fundus
flecks taken together reflect the severity of STGD1. Thus, the
severity of the disease very well influences the functional
outcome reflected in the scotopic 15-Hz flicker ERG. We con-
clude that all single parameters have to be considered in
connection, to evaluate disease severity, even though visual
acuity alone is a very important measure.
Mutational analysis of the ABCA4 gene revealed missense,
nonsense, frameshift, and splice mutations in our study group.
Although the majority of patients were shown to carry two
missense (mild-moderate mutation) or one missense and one
protein truncating mutation (severe mutation), five probands
all share the splice mutation 2588G3C on one allele and, in
addition, have a protein-truncating mutation (nonsense or
splice mutation) on the second. The 2588G3C transversion is
a relatively common mutation but is also present in control
individuals with a surprisingly high allele frequency.7,10 It has
TABLE 3. Canonical Correlation between the Slow and Fast Rod ERG Signals and the Standard ERG Parameters
Rod Response b-Wave Maximum Response a-Wave Maximum Response b-Wave
Amplitude Implicit Time Amplitude Implicit Time Amplitude Implicit Time
ERG amplitudes: slow rod
ERG pathway
r 0.70 0.63 0.63
P 0.0001 — 0.0001 — 0.0001 —
n 54 54 54
ERG amplitudes: fast rod
ERG pathway
r 0.62 0.50 0.52
P 0.0001 — 0.0001 — 0.0001 —
n 54 54 54
ERG phases: slow rod
ERG pathway
r 0.19 0.44 0.37
P — 0.36 — 0.002 — 0.06
n 26 46 26
ERG phases: fast rod
ERG pathway
r 0.27 0.32 0.37
P — 0.15 — 0.02 — 0.04
n 31 50 31
Canonical correlations of the amplitudes and phases of both the slow and fast rod ERG signals with the respective measures derived from the
standard ERG. The data provide the canonical correlation coefficient (r), the probability (P, not corrected for multiple comparisons), and the
sample size (n).
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been calculated that the predicted homozygote frequency for
this allele alone is greater than the estimated 1 in 10,000
incidence of STGD1.7 Taking this into account, as well as the
observed scarcity of 2588G3C homozygotes, Maugeri et al.7
suggested that 2588G3C may be a mild mutation, only caus-
ing disease when in combination with a severe allele. A recent
functional study has supported this view and shown that the
two products of the 2588G3C mutation, G863A and delG863,
produce a substantially impaired and a mildly impaired protein,
respectively.61 Genetically, our STGD1 study group therefore
appears to be relatively uniform, in the sense that in none of
the patients there were two protein-truncating disease alleles.
This and the fact that the number of patients with a certain
combination of disease alleles was too small does not make any
specific correlation between mutation-combination of muta-
tion and clinical phenotype meaningful.
Within the photoreceptor outer segments, ABCA4 localizes
to the disc rather than the plasma membrane, and within the
disc membrane it is confined to the rim.3,62 This localization
strongly suggests that ABCA4 catalyzes the intracellular rather
than intercellular transport of a substrate. The recently de-
scribed phenotype of ABCA4 knockout mice strongly supports
a role for the ABCA4 transporter in intraphotoreceptor retinoid
transport. The targeted mice show more all-trans retinal and
less all-trans retinol in the retina after acute light exposure,
and, over time, they accumulate A2-E in the RPE, presumably
because of the build-up of all-trans retinal within the photore-
ceptor disc membranes.18 These data suggest that ABCA4 nor-
mally transports or extracts all-trans retinal from the disc
membranes (after its release from photoactivated rhodopsin),
presenting it as a substrate for all-trans retinal dehydrogenase,
the enzyme within the outer segment that converts all-trans
retinal to all-trans retinol before its export and subsequent
reisomerization in the RPE.63 It has been proposed that ABCA4-
mediated photoreceptor death finally results from loss of the
RPE support function.18 Accordingly, the a-wave is normal in
young ABCA4 knockout mice, but abnormal in older animals.
This suggests that the ERG amplitude reductions (for both the
slow and fast rod ERG pathways) we found in patients with
STGD1 result from secondary photoreceptor effects mediated
by the loss of the RPE support function. This mechanism at the
RPE-photoreceptor level renders unexplained the differently
affected timing of the rod ERG signals we found in our patients.
However, one should be cautious about directly deducing
the morphologic and functional consequences for the human
disease from the ABCA4 knockout mouse model. In a human
retina with longstanding fundus flavimaculatus, histologic
study indicated, apart from shortened outer segments and
photoreceptor loss, reactive Mu¨ller cell hypertrophy, and ac-
cumulation of lipofuscin in the photoreceptor inner segments
peripheral to the macular area. This latter observation derived
from a rod-dominated fundus region may serve as an explana-
tion of the phase lag (time delay) we observed in the slow rod
pathway of our patients, if we assume that the rod–cone gap
junctions and the cone inner segments remain relatively intact.
Accumulation of metabolites in the rod inner segments may
well impair the signal flow to rod ON bipolar cells in the slow
rod pathway. Similar observations have been made in retinitis
pigmentosa, an inherited rod photoreceptor dystrophy. Some
patients with this disease (e.g., patients with a rhodopsin
intron 4 splice-site mutation) show disproportional postrecep-
toral function loss in the ERG that cannot be explained by
photoreceptor outer segment loss alone.64,65 Histologic studies
in mice expressing the rhodopsin Q344ter transgene have
revealed abnormal accumulation of the mutant gene product in
the inner segment,66 which, in addition to outer segment
dysfunction, may impair synaptic transmission of the rod outer
segment signal. In a single patient with the rhodopsin Q344ter
mutation, we have observed abnormal timing only in the slow
rod ERG signals derived from the scotopic 15-Hz flicker ERG,27
which suggests damage not only at the level of the outer
segments but also at or proximal to the photoreceptor terminal
region. It is tempting to speculate whether the phase lag we
observed only in the slow rod ERG signals of patients with
STGD1 reflects a similar disease mechanism.
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